NCT00829205WithdrawnPhase 1
A Phase I/II Study of Methylselenocysteine (MSC) in Combination With Immunochemotherapy (R-ICE) in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Withdrawn
- Sponsor
- Cancer Research UK
- Locations
- 5
- Primary Endpoint
- Dose-limiting toxicity and maximum tolerated dose of Se-methyl-seleno-L-cysteine (MSC) (Phase I)
Study Overview
Brief Summary
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer cell growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer cell-killing substances to them. Drugs used in chemotherapy, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Se-methyl-seleno-l-cysteine may help reduce the side effects of chemotherapy.
PURPOSE: This phase I/II trial is studying the side effects and best dose of Se-methyl-seleno-l-cysteine when given together with rituximab, ifosfamide, carboplatin, and etoposide and to see how well it works in treating patients with diffuse large B-cell lymphoma that has relapsed or not responded to treatment.
Detailed Description
OBJECTIVES:
Primary
- To assess dose-limiting toxicity and maximum-tolerated dose (MTD) of Se-methyl-seleno-L-cysteine (MSC) (to achieve a trough serum selenium [Se] concentration of > 20 μmol/L) prior to and in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in patients with relapsed or refractory diffuse large B-cell lymphoma. (Phase I)
- To determine the overall response rate to R-ICE given in addition to MSC at the MTD in these patients. (Phase II)
Secondary
- To determine the toxicity of R-ICE when used in combination with MSC in these patients.
- To determine the effect of MSC dosing on serum and intracellular Se and Se species in these patients.
- To determine the pharmacokinetics of MSC after single and multiple daily dosing in these patients.
- To investigate the effect of MSC dosing on Se-dependent processes (e.g., NFκB activity and AKT).
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed, CD20+, diffuse large B-cell lymphoma (DLBCL) according to WHO lymphoma classification
- •Histological transformation of a previously known indolent lymphoma allowed
- •Biopsy-proven DLBCL arising from an indolent lymphoma not diagnosed previously allowed
- •Disease in first relapse after complete remission, partial response (PR), or less than a PR after first-line of treatment
- •No primary CNS lymphoma
- •PATIENT CHARACTERISTICS:
- •ECOG performance status 0-2
- •Life expectancy > 3 months
- •Serum creatinine < 150 μmol/L
- •Serum bilirubin < 35 μmol/L
- •Transaminases < 2.5 times upper limit of normal (unless attributed to lymphoma)
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception
- •No contraindication to any of the drugs contained in the immunochemotherapy regimen
- •No other malignancy within the past 2 years, except basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
- •No other serious active disease that, in the opinion of the investigator, would preclude the patient from having conventional chemotherapy
- •No HIV positivity
- •No medical or psychiatric conditions that compromise the patient's ability to give informed consent
- •PRIOR CONCURRENT THERAPY:
- •Not specified
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Dose-limiting toxicity and maximum tolerated dose of Se-methyl-seleno-L-cysteine (MSC) (Phase I)
Overall response rate (Phase II)
Secondary Outcomes
- Toxicity as assessed by NCI CTCAE v 3.0
- Serum and intracellular Se and Se species
- Pharmacokinetics of MSC
- Protein markers of selenium activity
Investigators
Study Sites (5)
Loading locations...
Similar Trials
Completed
Phase 1
Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaLymphomaNCT00244985Roswell Park Cancer Institute42
Completed
Phase 2
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System LymphomaNeurotoxicityRadiation ToxicityChemotherapeutic Agent ToxicityCognitive/Functional EffectsLymphomaNCT01399372Radiation Therapy Oncology Group91
Unknown
Phase 2
GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin LymphomaLymphomaNCT00896519French Innovative Leukemia Organisation30
Terminated
Phase 2
Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System LymphomaLymphomaNCT00335140Eastern Cooperative Oncology Group26
Completed
Phase 2
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's LymphomaLymphomaNCT00392834AIDS Malignancy Consortium34